secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0000950170-25-042660
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences FY 2024 net loss narrows to $40.2M; pipeline advancing with multiple data readouts in 2025
--------------------------------------------------------------------------------

- Net loss $40.2M ($6.69/share) narrowed from $61.2M ($13.38/share) in 2023; collaboration revenue $28.5M vs $7.2M.
- Cash $112.1M at year-end; projected to fund operations into mid-2026.
- Received $20.1M equity investment and $10M accelerated funding from Gilead.
- Phase 1b data for ABI-4334 (HBV capsid modulator) showed mean 2.9 log10 IU/mL HBV DNA decline in 150mg cohort.
- Interim Phase 1b efficacy data for ABI-5366 and ABI-1179 (genital herpes) expected fall 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017025042660/0000950170-25-042660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017025042660/asmb-20250320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer